Merck Floats Vioxx Re-Stock
For its part, Merck has suggested that a relaunch may make sense due to the unique characteristics of Vioxx. For starters, the company has always pointed to Vioxx as the only Cox-2 inhibitor that has been labeled as safer on the stomach than older painkillers. In addition, it is the only Cox-2 drug that can be used by patients with certain allergies. Some patients have been pleading for a return of the drug despite its cardiac risks.
Even so, Merck could face an uphill battle if it actually decides to pursue the drug's return.
"Given that Merck decided voluntarily to withdraw Vioxx, the possibility of re-launching was always present," wrote Lehman Brothers analyst Anthony Butler, who has a neutral rating on the stock. But, "We believe that there are likely to be multiple hurdles for Merck to overcome should they decide to re-launch."
Prior to its recall, Vioxx ranked as one of the most heavily marketed -- and prescribed -- drugs in the country. It once generated about $2.5 billion in annual sales.
Select the service that is right for you!COMPARE ALL SERVICES
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV